• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Disease modifying treatment in multiple sclerosis.

作者信息

Fuller G N, Bone I

机构信息

Department of Neurology, Gloucester Royal Hospital, UK.

出版信息

J Neurol Neurosurg Psychiatry. 2001 Dec;71 Suppl 2(Suppl 2):ii20-1. doi: 10.1136/jnnp.71.suppl_2.ii20.

DOI:10.1136/jnnp.71.suppl_2.ii20
PMID:11701780
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC1765573/
Abstract
摘要

相似文献

1
Disease modifying treatment in multiple sclerosis.多发性硬化症的疾病修饰治疗
J Neurol Neurosurg Psychiatry. 2001 Dec;71 Suppl 2(Suppl 2):ii20-1. doi: 10.1136/jnnp.71.suppl_2.ii20.
2
First-line disease-modifying therapies in paediatric multiple sclerosis: a comprehensive overview.儿童多发性硬化的一线疾病修正治疗：全面概述。
Drugs. 2012 Jun 18;72(9):1195-211. doi: 10.2165/11634010-000000000-00000.
3
To treat, or not to treat: the therapeutic dilemma of idiopathic monosymptomatic demyelinating syndromes.治疗还是不治疗：特发性单症状脱髓鞘综合征的治疗困境
Arch Neurol. 2000 Jul;57(7):930-2. doi: 10.1001/archneur.57.7.930.
4
[Side-effects of the treatment with disease modifying drugs in patients with multiple sclerosis: an analysis of register data in the Yaroslavl region].[多发性硬化症患者使用疾病修饰药物治疗的副作用：对雅罗斯拉夫尔地区登记数据的分析]
Zh Nevrol Psikhiatr Im S S Korsakova. 2012;112(8):27-33.
5
Newer long-term treatments for multiple sclerosis.多发性硬化症的新型长期治疗方法。
Clin Neurol Neurosurg. 2002 Jul;104(3):265-71. doi: 10.1016/s0303-8467(02)00050-1.
6
[Logistics and description of treatment technology (the protocol for using disease modifying drugs--DMD)].[治疗技术的后勤保障与描述（使用疾病修正药物——DMD的方案）]
Zh Nevrol Psikhiatr Im S S Korsakova. 2011;111(2 Pt 2):93-8.
7
What is new in the treatment of multiple sclerosis?多发性硬化症治疗方面有哪些新进展？
Drugs. 2000 Mar;59(3):401-10. doi: 10.2165/00003495-200059030-00002.
8
Key issues in the diagnosis and treatment of multiple sclerosis. An overview.多发性硬化症诊断与治疗的关键问题。综述。
Neurology. 2002 Sep 24;59(6 Suppl 3):S1-33. doi: 10.1212/wnl.59.6_suppl_3.s1.
9
[Possibilities and limits of immunotherapy in multiple sclerosis. Inflammatory and degenerative aspects of the disease require a new pathogenetic concept].[多发性硬化症免疫治疗的可能性与局限性。该疾病的炎症和退行性方面需要一个新的发病机制概念]
Nervenarzt. 2003 Jun;74(6):537-8; discussion 539. doi: 10.1007/s00115-003-1523-4. Epub 2003 May 14.
10
Comment on Shuhaibar et al.: Favourable effect of immunomodulator therapy on bone mineral density in multiple sclerosis.关于舒海巴尔等人的评论：免疫调节剂疗法对多发性硬化症骨密度的有利影响。
Ir J Med Sci. 2009 Jun;178(2):235-6; author reply 237-8. doi: 10.1007/s11845-009-0275-y. Epub 2009 Jan 31.

引用本文的文献

1
Favorable outcome of early treatment of new onset child and adolescent migraine-implications for disease modification.新发性儿童和青少年偏头痛早期治疗的良好结果——对疾病改善的意义
J Headache Pain. 2009 Aug;10(4):227-33. doi: 10.1007/s10194-009-0133-3. Epub 2009 Jun 9.

本文引用的文献

1
The cost of delaying treatment in multiple sclerosis: what is lost is not regained.
Neurology. 2001 Jun 26;56(12):1620. doi: 10.1212/wnl.56.12.1620.
2
Randomized controlled trial of interferon-beta-1a in secondary progressive MS: MRI results.β-干扰素-1a治疗继发进展型多发性硬化症的随机对照试验：MRI结果
Neurology. 2001 Jun 12;56(11):1505-13. doi: 10.1212/wnl.56.11.1505.
3
Systematic review of immunomodulatory drugs for the treatment of people with multiple sclerosis: Is there good quality evidence on effectiveness and cost?用于治疗多发性硬化症患者的免疫调节药物的系统评价：是否有关于有效性和成本的高质量证据？
J Neurol Neurosurg Psychiatry. 2001 May;70(5):574-9. doi: 10.1136/jnnp.70.5.574.
4
Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group.在多发性硬化症首次脱髓鞘事件期间开始的肌肉注射干扰素β-1a治疗。CHAMPS研究组。
N Engl J Med. 2000 Sep 28;343(13):898-904. doi: 10.1056/NEJM200009283431301.
5
Population based cost utility study of interferon beta-1b in secondary progressive multiple sclerosis.基于人群的干扰素β-1b治疗继发进展型多发性硬化症的成本效用研究。
BMJ. 1999 Dec 11;319(7224):1529-33. doi: 10.1136/bmj.319.7224.1529.
6
Interferons in the treatment of multiple sclerosis: do they prevent the progression of the disease?干扰素治疗多发性硬化症：它们能阻止疾病进展吗？
Arch Neurol. 1998 Dec;55(12):1578-80. doi: 10.1001/archneur.55.12.1578.
7
Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG).肌肉注射干扰素β-1a治疗复发型多发性硬化症的疾病进展。多发性硬化症协作研究组（MSCRG）。
Ann Neurol. 1996 Mar;39(3):285-94. doi: 10.1002/ana.410390304.
8
Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group.共聚物1降低复发率并改善复发缓解型多发性硬化症的残疾状况：一项III期多中心、双盲、安慰剂对照试验的结果。共聚物1多发性硬化症研究组。
Neurology. 1995 Jul;45(7):1268-76. doi: 10.1212/wnl.45.7.1268.